查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933886

眼结核药物市场按药物类别、给药途径、通路和最终用户划分，全球预测（2026-2032年）

Ocular Tuberculosis Therapeutics Market by Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年眼结核病药物市场价值为 7,234 万美元，预计到 2026 年将成长至 7,728 万美元，年复合成长率为 6.50%，到 2032 年将达到 1.1245 亿美元。

关键市场统计数据
基准年 2025 7234万美元
预计年份：2026年 7728万美元
预测年份 2032 1.1245亿美元
复合年增长率 (%) 6.50%

全面推广眼结核药物治疗：临床复杂性、多学科诊疗需求及商业性驱动因素框架

眼结核的诊断和治疗面临独特的挑战，需要从临床、监管和商业性观点采取综合性方法。眼部组织的结核分枝桿菌感染通常表现出多种症状，造成诊断上的不确定性，也使得早期疗育困难。因此，治疗方法必须将全身抗结核治疗与局部眼部给药策略结合，以控制感染疾病并保护视力。

标靶递送技术的进步、药物管理的演变以及分销方式的改变，正在重新定义治疗路径和商业性机会。

由于药物研发、给药技术和诊断准确性的进步，眼结核的治疗模式正在改变性变化。製剂科学的进步使人们对标靶眼部给药，特别是玻璃体内注射和局部给药产生了浓厚的兴趣，这些给药方式能够将活性成分集中在病灶部位，同时降低全身毒性。口服和注射的同步研发不断完善全身性治疗方案，提高了耐受性和依从性，而这正是长期疾病管理的关键所在。

对2025年美国关税对眼科药品供应链网络的供应链、筹资策略和采购趋势的影响进行定性分析

2025年美国关税对全球医药原料和成品供应链产生了复杂的影响，并对眼科结核病药物的生产、采购和分销产生了连锁反应。关税带来的成本压力加速了筹资策略的调整，促使製造商重新评估其区域生产基地。为此，一些供应商正在采用近岸外包和双重采购策略，以在降低成本波动的同时维持供应的连续性。

基于深度细分的洞察，将药物类别、给药途径、分销管道和终端用户环境与临床应用和商业策略联繫起来。

细分市场分析揭示了治疗和商业动态的细微差别，这对制定药物研发和上市策略至关重要。以药物类别细分市场发现，第一线药物（例如乙胺丁醇、异烟肼、Pyrazinamide和利福平）仍然是标准全身治疗的基石，而二线药物（例如Aminoglycosides、环丝氨酸和Fluoroquinolones）则选择性地用于抗药性或难治性病例，并且需要谨慎管理和监测眼部毒性。这种区分清晰地揭示了临床使用模式、安全性监测要求以及对处方集决策者的价值提案。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和供应链模式正在影响治疗方法的采纳和可及性。

区域趋势显着影响眼结核药物的临床实务模式、法规环境和供应链结构。美洲的医疗保健体係以专科治疗中心和医院眼科计画结合为特征，强调实证通讯协定和协调的诊疗路径。该地区通常优先考虑健全的药物警戒和标准化的监测框架，从而影响临床对产品安全性和上市后资料收集的预期。

公司层面的竞争和营运考量，包括配方差异化、无菌生产伙伴关係以及基于证据的商业化。

眼结核治疗领域的竞争格局受到现有抗结核药物生产商、专业眼科产品开发商以及专注于无菌生产和分销的服务供应商的共同影响。现有抗结核药物生产商继续利用其已确立的安全性和有效性，而专业开发商则致力于透过新型配方、靶向眼部给药系统和提高耐受性来实现差异化。随着企业寻求缩短玻璃体内注射和局部局部候选药物的临床上市时间，上游活性药物原料药供应商与下游製药和医疗设备生产商之间的合作日益普遍。

针对研发、供应链韧性、临床医师参与和支付方合作等方面，提出切实可行且影响深远的建议，以加速临床应用。

产业领导者应采取多管齐下的方法，将临床开发与切实可行的供应和商业化策略结合。首先，他们应优先开发支持标靶眼部给药且与现有全身性疗法相容的製剂。眼部耐受性和局部药物动力学的证据将决定临床医师是否接受该製剂。其次，他们应透过多元化采购管道、确保区域生产能力以及建立合格的无菌填充和包装伙伴关係来增强供应链的韧性，尤其是在预填充式注射器和玻璃体内注射製剂方面。

采用严谨的多源研究途径，整合临床证据、监管审查、供应链访谈和竞争格局分析，以确保获得可靠的洞见。

本分析所依据的研究整合了临床文献、监管指南、供应链资讯和相关人员访谈，旨在整体情况眼部结核病药物。临床综合分析纳入了关于分枝桿菌感染疾病眼部表现的同行评审研究、抗结核药物在眼组织中的药物动力学特征以及与眼科给药和监测相关的安全性数据。监管审查则着重于局部眼部给药系统的核准途径、无菌生产需求以及影响上市时间的区域性要求。

简洁扼要的结论强调了将治疗创新转化为改善患者疗效所需的临床、生产和商业性优先事项的整合方法。

眼结核的治疗管理涉及感染疾病理学、眼科给药科学和复杂的医疗物流等多个领域。应对这项挑战需要综合解决方案，兼顾病患安全、临床工作流程以及无菌生产和特殊药品分销的实际操作。策略性地关注靶向眼科给药、製剂耐受性和稳健的供应链实践，对于将科学进步转化为更好的临床疗效至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的眼结核药物市场

  • 首选药物
    • 乙胺丁醇
    • 异烟肼
    • Pyrazinamide
    • 利福平
  • 二线药物
    • Aminoglycosides
    • 环丝胺酸
    • Fluoroquinolones

9. 依给药途径分類的眼结核药物市场

  • 注射
    • 预填充式注射器
    • 管瓶
  • 玻璃体内注射
  • 口服
    • 胶囊
    • 悬浮液
    • 药片
  • 局部用药
    • 眼药水
    • 软膏

第十章 眼结核药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 依最终用户分類的眼结核药物市场

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章 各地区眼结核药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 眼结核药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国眼结核药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国眼结核病药物市场

第十六章 中国眼结核药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca
  • Bayer HealthCare AG
  • Biological E
  • BioVersys
  • Cadila Pharmaceuticals
  • Cipla Limited
  • Concept Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited
  • Infectex
  • Johnson & Johnson
  • Labatec-Pharma SA
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Maneesh Pharmaceuticals
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pharmasyntez
  • Sandoz
  • Sanofi SA
  • Sequella, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Themis Medicare Ltd.
  • Viatris Inc.
Product Code: MRR-C36616F699A4

The Ocular Tuberculosis Therapeutics Market was valued at USD 72.34 million in 2025 and is projected to grow to USD 77.28 million in 2026, with a CAGR of 6.50%, reaching USD 112.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 72.34 million
Estimated Year [2026] USD 77.28 million
Forecast Year [2032] USD 112.45 million
CAGR (%) 6.50%

Comprehensive introduction to ocular tuberculosis therapeutics that frames clinical complexity, multidisciplinary care imperatives, and commercial decision drivers

Ocular tuberculosis presents distinctive diagnostic and therapeutic challenges that demand integrated clinical, regulatory, and commercial perspectives. Mycobacterial infection of ocular tissues often manifests with heterogenous signs, creating diagnostic ambiguity that complicates early intervention. Consequently, therapeutic approaches must reconcile systemic anti-tubercular regimens with localized ocular delivery strategies to preserve vision while managing infection.

Contemporary clinical practice emphasizes coordinated multidisciplinary care, where ophthalmologists, infectious disease specialists, and pharmacists collaborate to calibrate drug selection, dosing, and monitoring for toxicity. This clinical backdrop shapes therapeutic development priorities: agents that balance mycobacterial potency with ocular tolerability, formulations that permit targeted intraocular delivery, and dosing regimens that minimize systemic adverse events while ensuring adherence.

From a commercial standpoint, stakeholders must navigate regulatory nuances, variable reimbursement pathways, and the infrastructure needs of specialty clinics and hospital pharmacies that dispense complex anti-tubercular therapies. Emerging diagnostic modalities and surgical adjuncts are also shifting clinical algorithms, influencing demand for specific drug classes and routes of administration. Against this landscape, strategic decisions should be grounded in an understanding of clinical unmet needs, provider workflows, and the interplay between systemic and localized treatment modalities.

How advances in targeted delivery, evolving drug stewardship, and shifting distribution practices are redefining therapeutic pathways and commercial opportunities

The therapeutic landscape for ocular tuberculosis is undergoing transformative shifts driven by advancements in drug development, delivery technologies, and diagnostic precision. Progress in formulation science has elevated interest in targeted ocular administration, particularly intravitreal and topical approaches that aim to concentrate active agents at the site of disease while mitigating systemic toxicity. Parallel developments in oral and injectable formulations continue to refine systemic therapy options by improving tolerability and adherence, which are central to long-term disease control.

Innovations in pharmacology are reshaping expectations around second-line agents and combination regimens; antimicrobial stewardship and resistance surveillance are prompting more selective use of aminoglycosides, cycloserine, and fluoroquinolones, while classical first-line agents such as ethambutol, isoniazid, pyrazinamide, and rifampicin remain foundational to treatment algorithms. At the same time, the industry is responding to clinician demand for clearer guidance on ocular safety profiles, dosing adjustments, and monitoring protocols.

Health systems are also evolving: hospital pharmacies and specialty clinics are enhancing capacity for compounding and sterile preparation, while online pharmacy channels are expanding access to specific formulations under regulated distribution frameworks. These shifts are creating opportunities for companies that can deliver validated, ocular-specific formulations and for service providers that offer integrated supply chain and compliance support. As clinical evidence accumulates and delivery platforms mature, the balance between systemic and local therapies will be a defining axis of competitive differentiation.

Qualitative analysis of how the 2025 United States tariffs reshaped supply chains, sourcing strategies, and procurement dynamics across ocular therapeutic supply networks

The imposition of United States tariffs in 2025 has introduced a complex overlay to global supply chains for pharmaceutical inputs and finished products, with cascading effects across manufacturing, procurement, and distribution of ocular tuberculosis therapeutics. Tariff-driven cost pressures have accelerated strategic reviews of sourcing strategies and prompted manufacturers to reassess regional production footprints. In response, some suppliers are pursuing nearshoring or dual-sourcing approaches to preserve continuity of supply while containing cost volatility.

Clinicians and procurement teams are navigating the operational implications of these supply chain shifts as they evaluate formulary choices and inventory policies. Hospital pharmacies and specialty clinics that rely on prefilled syringes, vials, and certain specialized excipients have encountered variability in lead times, triggering the implementation of more conservative stocking policies and enhanced supplier qualification processes. Simultaneously, manufacturers are increasing transparency around upstream input risk and adjusting contractual terms to share risk across the value chain.

Regulatory bodies and payers are also reacting to the tariff environment by strengthening scrutiny of cost pass-through and by encouraging alternative sourcing to protect patient access. For companies operating across multiple regions, the cumulative impact of the tariffs underscores the importance of supply chain flexibility, inventory resilience, and proactive pricing strategies that preserve affordability for end users while sustaining commercial viability for manufacturers.

Deep segmentation-driven insights linking drug classes, administration routes, distribution channels, and end-user settings to clinical adoption and commercial strategy

Segmentation analysis reveals nuanced therapeutic and commercial dynamics that are essential for targeting development and go-to-market strategies. Within drug class segmentation, first-line agents-ethambutol, isoniazid, pyrazinamide, and rifampicin-continue to anchor standard systemic regimens, whereas second-line options such as aminoglycosides, cycloserine, and fluoroquinolones are deployed selectively in resistant or refractory cases, necessitating careful stewardship and monitoring for ocular toxicity. This differentiation drives distinct clinical use patterns, safety monitoring requirements, and value propositions for formulary decision-makers.

Route of administration segmentation further differentiates product opportunity and adoption pathways. Injectable formats, available as prefilled syringes or vials, are integral for inpatient and surgical settings where sterile preparation and immediate dosing are priorities. Intravitreal delivery addresses the need for targeted intraocular concentrations in sight-threatening cases, while oral formulations-spanning capsules, suspensions, and tablets-support systemic therapy across ambulatory settings. Topical modalities, including eye drops and ointments, serve both adjunctive roles and localized therapeutic intent, particularly in milder or predominantly anterior ocular involvement. Each route imposes distinct regulatory and manufacturing requirements, as well as different clinical workflows for administration and monitoring.

Distribution channel segmentation underscores how access and continuity of care are mediated through hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies and specialty clinics often manage complex compounding and cold-chain needs, while online pharmacy channels can extend reach to ambulatory patients under appropriate oversight. Retail pharmacies support community-level access and adherence through counseling and refill management. End user segmentation identifies ambulatory surgery centers, hospitals, and specialty clinics as primary settings for treatment delivery, each with differing procedural capabilities, procurement cycles, and clinician specializations that influence product adoption patterns and commercial engagement strategies.

Regional clinical, regulatory, and supply chain patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that shape therapeutic adoption and access

Regional dynamics substantially influence clinical practice patterns, regulatory environments, and supply chain architectures in ocular tuberculosis therapeutics. In the Americas, healthcare systems display a mix of specialty centers and hospital-based ophthalmology programs that emphasize evidence-driven protocols and coordinated care pathways. This region often prioritizes robust pharmacovigilance and standardized monitoring frameworks, which shape clinical expectations for product safety and post-market data collection.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory regimes and healthcare infrastructure vary widely. In some markets, centralized hospital systems provide concentrated specialist expertise, enabling adoption of advanced intravitreal and injectable therapies, while in other settings, constrained resources increase reliance on oral regimens and simplified delivery models. Stakeholders in this region must navigate divergent reimbursement norms and capacity constraints, driving demand for flexible formulations and scalable distribution solutions.

Asia-Pacific exhibits rapidly evolving clinical capabilities, expanding specialty ophthalmology networks, and growing investment in local pharmaceutical manufacturing. Increasing diagnostic capacity and rising clinical awareness of ocular manifestations are amplifying demand for tailored therapeutic options across both inpatient and outpatient settings. Across all regions, alignment between regulatory expectations, supply chain resilience, and clinician training will determine how new formulations and delivery modalities are integrated into routine care.

Competitive and operational company-level considerations including formulation differentiation, sterile manufacturing partnerships, and evidence-driven commercialization

Competitive dynamics in ocular tuberculosis therapeutics are influenced by a combination of established anti-tubercular manufacturers, specialty ophthalmic product developers, and service providers focused on sterile manufacturing and distribution. Established producers of first-line anti-tubercular agents continue to leverage recognized safety and efficacy profiles, while specialty developers differentiate through novel formulations, targeted ocular delivery systems, and improved tolerability. Partnerships between upstream active pharmaceutical ingredient suppliers and downstream compounding or device manufacturers are increasingly common as firms seek to accelerate time-to-clinic for intravitreal and topical candidates.

In parallel, contract development and manufacturing organizations that provide sterile fill-finish and prefilled syringe capabilities are gaining strategic importance, especially as demand for injectable and intravitreal products expands. Companies that combine clinical evidence generation with robust supply chain capabilities are positioned to capture specialist formularies and long-term institutional contracts. Additionally, providers that can support multi-region regulatory submissions and real-world evidence programs will have an advantage in demonstrating value to payers and health systems.

Ultimately, success in this category will depend on a firm's ability to integrate clinical credibility, manufacturing quality, and commercial access strategies. Firms that invest in clinician education, post-market surveillance, and collaborative supply agreements will be better equipped to meet the operational and clinical complexities inherent in ocular tuberculosis care.

Actionable, high-impact recommendations for development, supply chain resilience, clinician engagement, and payer alignment to accelerate clinical adoption

Industry leaders should adopt a multifaceted approach that aligns clinical development with pragmatic supply and commercialization strategies. First, prioritize development of formulations that support targeted ocular delivery while maintaining compatibility with established systemic therapies; evidence on ocular tolerability and local pharmacokinetics will be decisive for clinician uptake. Second, build supply chain resilience through diversified sourcing, regional manufacturing capacity, and qualified partnerships for sterile fill-finish, particularly for prefilled syringes and intravitreal presentations.

Third, invest in clinician engagement and education programs that clarify monitoring protocols, toxicity management, and patient selection for different routes of administration. Fourth, develop adaptive pricing and contracting models that recognize the procurement realities of hospitals, specialty clinics, and ambulatory surgery centers, while enabling access through online pharmacy channels where appropriate. Fifth, implement robust post-market surveillance and real-world evidence collection to support safety claims, inform label refinements, and satisfy payers' evidence needs.

Finally, anticipate regulatory and policy shifts by maintaining proactive dialogue with health authorities and by designing clinical development plans that generate the data required for both local approvals and cross-border recognition. By integrating these measures, organizations can reduce commercial risk, accelerate adoption, and deliver measurable improvements in patient outcomes.

Rigorous multi-source research approach integrating clinical evidence, regulatory review, supply chain interviews, and competitive mapping to ensure robust insights

The research underpinning this analysis synthesized clinical literature, regulatory guidance, supply chain intelligence, and stakeholder interviews to construct a holistic view of the ocular tuberculosis therapeutics landscape. Clinical synthesis incorporated peer-reviewed studies on ocular manifestations of mycobacterial infection, pharmacokinetic profiles of anti-tubercular agents in ocular tissues, and safety data relevant to ophthalmic dosing and monitoring. Regulatory review focused on approval pathways for localized ocular delivery systems, sterile manufacturing expectations, and region-specific requirements that influence time-to-market.

Supply chain and commercial analyses drew on interviews with hospital pharmacy directors, specialty clinic administrators, contract manufacturing partners, and distribution channel experts. These conversations informed assessments of procurement cycles, inventory management practices, and the operational considerations for prefilled syringe and vial formats, as well as oral and topical presentations. Competitive landscape mapping combined public product information, clinical development registries, and corporate disclosures to identify strategic positioning around formulation innovation and manufacturing capacity.

Throughout the research process, findings were triangulated across data sources to ensure validity and to surface actionable insights that reflect current practice and foreseeable operational constraints. Where primary data were limited, conservative inferences were made based on analogous therapeutic categories and validated through expert consultation to maintain analytic rigor.

Concise conclusion emphasizing integrated clinical, manufacturing, and commercial priorities required to translate therapeutic innovation into improved patient outcomes

The therapeutic management of ocular tuberculosis occupies an intersection of infectious disease pharmacology, ophthalmic delivery science, and complex healthcare logistics. Addressing this challenge requires integrated solutions that account for patient safety, clinician workflow, and the operational realities of sterile manufacturing and specialty distribution. Strategic emphasis on targeted ocular delivery, formulation tolerability, and robust supply chain practices will be critical for translating scientific advances into improved clinical outcomes.

Stakeholders should recognize that clinical adoption hinges on clarity of evidence and operational feasibility. Manufacturers that invest in clinical validation, clinician training, and reliable supply will be better positioned to meet the nuanced needs of hospitals, specialty clinics, and ambulatory surgery centers. Concurrently, policymakers and payers will play a decisive role in enabling access through supportive reimbursement frameworks and by incentivizing resilient sourcing strategies.

In sum, the field is poised for meaningful progress provided that development efforts are aligned with real-world care pathways and that commercial strategies proactively address the logistical and regulatory complexities of ocular therapeutics delivery. Collaboration across clinical, manufacturing, and commercial stakeholders will be essential to realize the full potential of new therapeutic approaches.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ocular Tuberculosis Therapeutics Market, by Drug Class

  • 8.1. First-Line Drugs
    • 8.1.1. Ethambutol
    • 8.1.2. Isoniazid
    • 8.1.3. Pyrazinamide
    • 8.1.4. Rifampicin
  • 8.2. Second-Line Drugs
    • 8.2.1. Aminoglycosides
    • 8.2.2. Cycloserine
    • 8.2.3. Fluoroquinolones

9. Ocular Tuberculosis Therapeutics Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Prefilled Syringe
    • 9.1.2. Vial
  • 9.2. Intravitreal
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Suspension
    • 9.3.3. Tablet
  • 9.4. Topical
    • 9.4.1. Eye Drops
    • 9.4.2. Ointments

10. Ocular Tuberculosis Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Ocular Tuberculosis Therapeutics Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Ocular Tuberculosis Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Ocular Tuberculosis Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Ocular Tuberculosis Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Ocular Tuberculosis Therapeutics Market

16. China Ocular Tuberculosis Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca
  • 17.6. Bayer HealthCare AG
  • 17.7. Biological E
  • 17.8. BioVersys
  • 17.9. Cadila Pharmaceuticals
  • 17.10. Cipla Limited
  • 17.11. Concept Pharmaceuticals Ltd.
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Glenmark Pharmaceuticals Limited
  • 17.14. Infectex
  • 17.15. Johnson & Johnson
  • 17.16. Labatec-Pharma SA
  • 17.17. Lupin Limited
  • 17.18. Macleods Pharmaceuticals Ltd.
  • 17.19. Maneesh Pharmaceuticals
  • 17.20. Novartis AG
  • 17.21. Otsuka Pharmaceutical Co., Ltd.
  • 17.22. Pfizer Inc.
  • 17.23. Pharmasyntez
  • 17.24. Sandoz
  • 17.25. Sanofi S.A.
  • 17.26. Sequella, Inc.
  • 17.27. Sun Pharmaceutical Industries Limited
  • 17.28. Teva Pharmaceutical Industries Limited
  • 17.29. Themis Medicare Ltd.
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ETHAMBUTOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ETHAMBUTOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ISONIAZID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PYRAZINAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PYRAZINAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RIFAMPICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CYCLOSERINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CYCLOSERINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CYCLOSERINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY FIRST-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY SECOND-LINE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA OCULAR TUBERCULOSIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)